UBS Group Cuts Owens & Minor (NYSE:OMI) Price Target to $25.00

Owens & Minor (NYSE:OMI) had its price target reduced by UBS Group from $28.00 to $25.00 in a research note published on Tuesday, Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms also recently commented on OMI. Barclays reduced their target price on Owens & Minor from $18.00 to $14.00 and set an “equal weight” rating on the stock in a report on Tuesday. Citigroup lowered their target price on shares of Owens & Minor from $21.00 to $18.50 and set a “buy” rating for the company in a research note on Tuesday. StockNews.com lowered shares of Owens & Minor from a “buy” rating to a “hold” rating in a report on Monday, August 26th. JPMorgan Chase & Co. dropped their price objective on shares of Owens & Minor from $22.00 to $18.00 and set an “underweight” rating on the stock in a research note on Wednesday, August 21st. Finally, Robert W. Baird decreased their target price on Owens & Minor from $19.00 to $14.00 and set a “neutral” rating for the company in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $18.50.

Owens & Minor Stock Performance

Owens & Minor stock opened at $11.78 on Tuesday. Owens & Minor has a 52 week low of $11.42 and a 52 week high of $28.35. The company has a current ratio of 1.09, a quick ratio of 0.51 and a debt-to-equity ratio of 2.17. The stock has a market cap of $908.24 million, a P/E ratio of -21.04, a price-to-earnings-growth ratio of 0.43 and a beta of 0.41. The stock has a 50 day moving average of $14.54 and a 200-day moving average of $16.19.

Owens & Minor (NYSE:OMI) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.01. The company had revenue of $2.72 billion during the quarter, compared to analyst estimates of $2.68 billion. Owens & Minor had a negative net margin of 0.40% and a positive return on equity of 14.66%. The firm’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period last year, the business earned $0.44 EPS. On average, analysts expect that Owens & Minor will post 1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Owens & Minor

Several large investors have recently made changes to their positions in the company. ProShare Advisors LLC increased its position in Owens & Minor by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 15,021 shares of the company’s stock valued at $416,000 after acquiring an additional 1,029 shares during the period. Texas Permanent School Fund Corp grew its stake in shares of Owens & Minor by 1.8% in the first quarter. Texas Permanent School Fund Corp now owns 66,953 shares of the company’s stock worth $1,855,000 after purchasing an additional 1,156 shares in the last quarter. DekaBank Deutsche Girozentrale increased its holdings in shares of Owens & Minor by 76.6% during the second quarter. DekaBank Deutsche Girozentrale now owns 3,126 shares of the company’s stock valued at $43,000 after purchasing an additional 1,356 shares during the period. Arizona State Retirement System raised its stake in shares of Owens & Minor by 7.7% during the second quarter. Arizona State Retirement System now owns 20,371 shares of the company’s stock valued at $275,000 after purchasing an additional 1,449 shares in the last quarter. Finally, Quarry LP raised its stake in shares of Owens & Minor by 290.1% during the second quarter. Quarry LP now owns 2,099 shares of the company’s stock valued at $28,000 after purchasing an additional 1,561 shares in the last quarter. Institutional investors and hedge funds own 98.04% of the company’s stock.

Owens & Minor Company Profile

Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers.